Want to join the conversation?
R&D expense for 3Q15 was $174.8MM, up $16.6MM YoverY. R&D increased primarily due to the impact of the acquired EPD business, which raised R&D by approx. $17MM in the current quarter. Additionally, R&D increased due to the continued development of $MYL respiratory, insulin and biologics programs, partially offset by lower expense on other programs.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?